Dorsal root ganglia atrophy and serum biomarkers supporting the diagnosis of chronic postsurgical inguinal pain - Herrmann, Eva; Schindehütte, Magnus; Kindl, Gudrun; Reinhold, Ann-Kristin; Aulbach, Felix; Rose, Norman; Dreiling, Johannes; Schwarzkopf, Daniel; Meir, Michael; Jin, Yuying; Teichmüller, Karolin; Widder, Anna; et al. (medRxiv, 2024)
Background Chronic postsurgical inguinal pain (CPIP) is the most common complication of groin hernia surgery. The characteristics of patients, their medical care, and choice of the best diagnostic tools remain to be defined to optimize preventive and therapeutic interventions.Methods Claims data from 2018 and a 1-year follow-up were analysed and deep phenotyping including sensory testing, blood and skin biopsies, MRI imaging of the dorsal root ganglion (DRG), and patient-reported outcomes were used to define normative values, as well as incidence, medical care, and pathophysiological factors.Results 11,221 patients with hernia surgery in 2018 were identified; 8.5% had pain before which was relieved by surgery, but a similar percentage had novel groin pain. Deep phenotyping of 141 healthy controls provided a map of the inguinal sensory system. CPIP patients suffered from moderate pain with neuropathic features, individual sensory abnormalities, and unilateral L1 DRG atrophy. In the blood, C-C-motif chemokine ligand (CCL2) and brain-derived neurotrophic factor (BDNF) were upregulated while apolipoprotein A1 (ApoA1) was reduced. A cluster of DRG atrophy, BDNF, ApoA1 and anxiety correlated best with the diagnosis. CPIP patients with novel pain had significantly more DRG atrophy (−22% ipsi vs. contra).Conclusion CPIP is relevant and often newly acquired after surgery. A combination of DRG imaging, serum markers, and anxiety screening can support the diagnosis. Using this core set of markers could guide surgeons towards more personalized therapies and possible preventive intraoperative techniques.Trial registration German Trial Registry DRKS00024588 and DRKS00016790Competing Interest StatementHR received consultant fees from Gruenenthal and Orion, and financial support for a study by Algiax. WM reports grants from Gruenenthal and Pfizer, personal fees from Tafalgie, Kyowa, Mundipharma, Gruenenthal, Ethypharm, and Spectrum Therapeutics. CS has received consulting fees from Algiax, Bayer, Grifols, Immunic, Merz, Roche, and Takeda Pharmaceuticals; and has given educational talks for Teva, CSL Behring, Grifols, GlaxoSmithKline, Takeda Pharmaceuticals, Pfizer, Amicus, and Alnylam. All other authors have no conflict of interest regarding this work.Funding StatementThis project was supported by the German Research Foundation KFO5001 ResolvePAIN # 42650386, the German Innovation Fund Project LOPSTER (FKz. 01VSF19019), the Graduate School of Life Sciences and the Chinese Scholarship Council.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the University of Wuerzburg, Germany, and the University of Jena, Germany, gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.